Search

Displaying results 2891 - 2900 of 4236 in total
  1. Drug

    Cystine

    go.drugbank.com/drugs/DB00138
    ApprovedInvestigationalNutraceuticalWithdrawn

    A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

  2. Drug

    Florbetaben F-18

    go.drugbank.com/drugs/DB09148
    ApprovedInvestigational

    Florbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaqu...

  3. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  4. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed fro...

  5. Drug

    Interferon Kappa

    go.drugbank.com/drugs/DB15749
    Experimental

    Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and

  6. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

  7. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condit...

  8. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

  9. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...

  10. Drug

    Demeclocycline

    go.drugbank.com/drugs/DB00618
    Approved

    A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.